Dear Editor

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global stir to health-systems and families. As of July 2020, SARS-CoV-2 has infected 13.4 million people and resulted in 580,552 deaths.[@bib0001] Recent literature has shown patients with SARS-CoV-2 are at risk for a host of devastating diseases such as acute respiratory distress syndrome, strokes, myocarditis, and venous thromboembolism. Here is a case of a patient diagnosed with SARS-CoV-2 presenting with pulmonary embolism.

A 68-year-old male presented to the Emergency Department (ED) with exertional shortness of breath, and fevers. He was diagnosed with SARS-CoV-2 ten days prior to presentation. At home he reported frequent episodes of fever with the highest reading of 103°F and his pulse oximeter showed oxygen saturation above 95%. On the day of his presentation, he developed exertional shortness of breath and his home pulse oximeter showed an oxygen level of 78%. When he reported to the ED, he was afebrile, heart rate was 111 bpm, respiratory rate was 18 breaths per minute, blood pressure was 143/79 mmHg, and oxygen saturation was 80% on room air. He was placed on a non-rebreather mask and maintained an oxygen saturation of 95%. His laboratory markers were significant for a D-dimer of 41,385 ng/mL, N-terminal pro b-type natriuretic peptide (NTproBNP) of 267 pg/mL, and troponin-T ≤0.01 ng/mL. EKG showed sinus tachycardia of 105 bpm. Chest x-ray showed hazy and patchy airspace opacities bilaterally. Given the acute onset of shortness of breath, hypoxia, and a very high d-dimer level, a CT Chest Pulmonary Angiography with IV Contrast (CTA) was ordered. A filling defect was seen in the left lower lobe subsegmental pulmonary arterial tree, with multiple additional filling defects visible in both lungs consistent with pulmonary emboli. Diffuse ground-glass and consolidative airspace opacities were seen in both lung fields consistent with SARS-CoV-2 infection ([Fig. 1](#fig0001){ref-type="fig"} , [Fig. 2](#fig0002){ref-type="fig"} ). The patient was started on therapeutic anticoagulation with heparin. After 5 days, the patient\'s hemoglobin oxygen saturation was 94% on room air, D-dimer was 2800 ng/mL, and he was discharged home with apixaban.FIGURE 1CT Chest Pulmonary Angiography with IV Contrast (CTA) showing filling defect consistent with pulmonary embolism.Fig 1:FIGURE 2CT Chest Pulmonary Angiography with IV Contrast (CTA) showing ground glass opacities.Fig 2:

Viral infections cause an activation of the host\'s coagulation system to possibly ward off the spread of the infection.[@bib0002] This occurs through a series of interactions between macrophages, monocytes, endothelial cells, platelets and lymphocytes.[@bib0003] ^.^ In patients with SARS-CoV-2, we have noticed more than expected clinically significant pulmonary embolisms. Phylogenetic studies show that the SARS-CoV-2 has around 80% sequence identity with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1).[@bib0004] There has been a significant amount of molecular genetic studies done on the prothrombotic nature of SARS-CoV-1. In vitro studies of SARS-CoV-1 have shown increased expression of fibrinogen factors II, III and X, thromboxane synthase (TBXAS) gene, Toll-like receptor 9 (TLR9). Other in vitro studies of SARS-COV-1 have also shown urokinase dysregulation.[@bib0002] ^,^ [@bib0003] It would not be of surprise that SARS-COV-2 shared these hypercoagulable genes and pathways. A retrospective study in Tongji hospital in Wuhan, China showed patients with sepsis-induced coagulopathy score ≥ 4, or D-dimer \>6-fold of upper limit of normal had a statistically significant reduced 28-day mortality when treated with mainly low molecular weight heparin compared to no heparin treatment.[@bib0005] Furthermore, a retrospective analysis in a New York City hospital system, showed treatment dose systemic anticoagulation (AC) in mechanically ventilated patients had a mortality rate of 29.1% as compared to 62.7% without AC.[@bib0006] Hospitals have adopted protocols for administration of higher prophylactic doses and full anticoagulation based on D-dimer levels without a diagnosed PE or deep venous thrombosis in patients with SARS-CoV-2.
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